Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 555 Triple Negative Breast Neoplasms 94 Inflammatory Breast Neoplasms 38 Breast Neoplasms, Male 31 Neoplasm Metastasis 27 Ovarian Neoplasms 25 Carcinoma, Non-Small-Cell Lung 23 Melanoma 21 Pancreatic Neoplasms 14 Neoplasms 14 Colorectal Neoplasms 13 Carcinoma, Renal Cell 12 Stomach Neoplasms 11 Multiple Myeloma 10 Lung Neoplasms 10 Carcinoma, Ovarian Epithelial 9 Carcinoma, Hepatocellular 9 Lymphoma, Non-Hodgkin 8 Sarcoma 7 Lymphoma, Follicular 7 Lymphoma 7 Carcinoma, Ductal, Breast 7 Recurrence 6 Neutropenia 6 Lymphoma, Mantle-Cell 6 Lymphoma, Large-Cell, Immunoblastic 6 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, B-Cell, Marginal Zone 6 Leukemia, Myeloid, Acute 6 Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Cyclophosphamide × Breast × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡